| Shanshan Chen,Shun Lu. Antiangiogenic agents combined with chemotherapy in non-small cell lung cancer. Oncol Transl Med, 2015, 1: 58-64. |
| Antiangiogenic agents combined with chemotherapy in non-small cell lung cancer |
| Received:February 16, 2015 Revised:March 31, 2015 |
| View Full Text View/Add Comment Download reader |
| KeyWord:non-small cell lung cancer (NSCLC); antiangiogenic agent; chemotherapy; combination schedule |
| Author Name | Affiliation | E-mail | | Shanshan Chen | Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China | chenshan1234cool@163.com | | Shun Lu | Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China | lushun131313@163.com |
|
| Hits: 6812 |
| Download times: 7958 |
| Abstract: |
| As one of targeting therapies, antiangiogenic treatment has increasingly been studied for advanced non-small cell lung cancer(NSCLC)and it proves effectiveness in treatment of advanced NSCLC. Bevacizumab, a monoclonal antibody targeting angiogenesis, is the only approved antiangiogenic agent in combination with first-line chemotherapy for non-squamous NSCLC. Small molecule inhibitors targeting the tyrosine kinase receptor have also shown promise when combined with standard chemotherapeutic agents in patients with advanced NSCLC. However, except bevacizumab, not all other antiangiogenic agents showed significant benefits when combined with chemotherapy. As for the failures of most of other combinations, the combination schedule maybe an important reason overlooked in clinical trials. This article reviews the combination of angiogenic agents with chemotherapy in treatment of NSCLC . |
| Close |
|
|
|